$2.706
+0.047 (+1.72%)終値時点
ELAB のニュース
ELAB のイベント
PMGC Holdings Registers NorthStrive DBA Name
PMGC Holdings announces that it has registered a doing-business-as name as NorthStrive Holdings, Inc. and entered into a Trademark License Agreement with NorthStrive Companies Inc., authorizing the company's use of the NorthStrive name, logo, and associated brand marks. NorthStrive Holdings has registered NorthStrive Holdings, Inc. as a DBA and will operate and present itself under that name in its M&A and operating business activities, creation, sponsorship and development of special purpose acquisition companies and various corporate communications, effective immediately. The license arrangement reflects the close strategic relationship between NorthStrive Holdings and NorthStrive Companies, which serves as the company's management and advisory firm, supporting its acquisition sourcing, transaction execution, and operational management activities, the company said.
PMGC Holdings Sponsors NorthStrive Acquisition Corp I.
PMGC Holdings announced that it is the sponsor of NorthStrive Acquisition Corp I., marking the launch of PMGC's special purpose acquisition company, SPAC, sponsorship platform.
PMGC Holdings Subsidiary Signs Statement of Work with Charles River Laboratories
PMGC Holdings (PMGC) announced that its subsidiary, NorthStrive Biosciences has executed a Statement of Work with Charles River Laboratories (CRL) to conduct analytical characterization supporting the development of NorthStrive Biosciences' EL-22 and EL-32 engineered probiotic programs. Under the SOW, Charles River will perform specialized analytical testing designed to characterize plasmid copy numbers in NorthStrive's engineered bacterial product candidates.
PMGC Terminates Letter of Intent to Acquire Arizona Company
PMGC announced that, following completion of audit-stage financial due diligence, it has terminated the previously announced non-binding letter of intent to acquire a 76% controlling interest in a privately held Arizona-based precision machining and contract manufacturing company. At the time of the announcement, PMGC stated that, based on unaudited financial information provided by the target, the business had generated approximately $5.46M in revenue and approximately $1.05M in EBITDA for fiscal year 2025. While PMGC continues to evaluate strategic acquisition opportunities, the company is also proactively investing in its existing aerospace and defense manufacturing businesses.
PMGC Enters Strategic Partnership with Orbit2Orbit
PMGC announced that it has entered into a non-binding term sheet with Orbit2Orbit outlining a proposed multi-part strategic relationship spanning space-based bioscience research, aerospace manufacturing, and a strategic investment by PMGC that would further expand the company's exposure to the growing commercial space economy. The proposed relationship is intended to combine capabilities across PMGC's operating businesses with Orbit2Orbit's spaceflight platform and its Mice2Space live-animal research capability, creating a differentiated framework to support biological research in microgravity while establishing a potential U.S.-based manufacturing relationship for future Orbit2Orbit space systems. Under the term sheet, the parties are contemplating three principal transactions. NorthStrive Biosciences, a wholly owned subsidiary of PMGC, and Orbit2Orbit intend to collaborate on the development and use of the Mice2Space live-animal research capability utilizing the Orbit2Orbit platform. NorthStrive Bio's study would evaluate its lead therapeutic candidates, EL-22 and EL-32, in mice for muscle retention and body composition outcomes in microgravity compared with Earth-based controls. The term sheet also contemplates A&B Aerospace serving as Orbit2Orbit's preferred U.S.-based manufacturing partner under a definitive agreement. As part of the proposed relationship, PMGC intends to subscribe for C$200,000 of Orbit2Orbit common shares at C$0.80 per share in connection with Orbit2Orbit's current private placement financing and proposed listing on the Canadian Securities Exchange through a reverse takeover transaction. The planned investment is intended to align PMGC with Orbit2Orbit's growth as the space technology company pursues its proposed public listing.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。